The team at a $75.887-billion-AUM (as of June 8) is looking to help FAs and their clients bet on "the biology revolution."

On June 3, the WisdomTree Investments, Inc. [profile] folks launched the WisdomTree BioRevolution Fund (ticker: WDNA on the CBOE). The new ETF is part of WisdomTree's Megatrends series.

WDNA is subadvised by Mellon Investments Corporation and PMed by Mellon's Marlene Walker-Smith, director and co-head of equity index portfolio management, and Thomas Durante, managing director and co-head of equity index portfolio management. The new ETF tracks the WisdomTree BioRevolution Index, and the index was developed leveraging data from special strategist Jamie Metzl, a technology futurist. The fund's expense ratio is 45 basis points.

Other vendors to the new include: Ernst & Young, LLP (independent accounting firm); Foreside Fund Services, LLC (distributor); Morgan, Lewis & Bockius LLP (counsel); and State Street Bank and Trust Company (administrator, custodian, securities lending agent, and transfer agent).

Jeremy Schwartz, WisdomTree's global head of research, puts the launch of the fund in the context of "a historic opportunity equivalent to the industry and internet revolutions."

"The WisdomTree BioRevolution Fund offers diversified exposure to a basket of companies that we believe is uniquely positioned to seize the opportunity at the intersection of biology and technology," Schwartz states.

"If the nineteenth was the century of chemistry and the twentieth of physics, the twenty-first will be the century of biology," Metzl states. "I am delighted to be collaborating with the amazing team at WisdomTree in uncovering the massive opportunities of this historic megatrend." 

Stay ahead of the news ... Sign up for our email alerts now
CLICK HERE